Q2 2026 Biotricity Inc Earnings Call & Business Update

Being recorded.

As a reminder, this is by ultra cities second quarter fiscal 2026 ended on September 32025. So.

So all figures presented for this period will reflect that.

Earlier Bioterror City issued its earnings press release for the period, which highlight our financial and operational results a copy of the press release is available on the Investor Relations section of Bioterror sees website and full financials have been filed with the SEC on Form 10-Q and posted on Edgar at Www Dot S.

E C dot Gov.

Before beginning the Companys formal remarks, I'd like to remind listeners today.

And that may contain forward looking statements that reflect management's current views with respect to future events any such statements are subject to risk and uncertainties that could cause actual results to differ materially from those projected in these forward looking statements.

<unk> does not undertake.

To update any forward looking statements except as required.

At this point I'm pleased to turn the call over to <unk> founder and CEO, Dr. Wykoff, Oh, sorry.

Thank you. Please go ahead.

Hi, everybody I would like to first thank everybody for joining us today.

For 2026 has been a pivotal year for Micra city defined by significant advancements and strategic initiatives that have brought us to the threshold of profitability.

Our relentless focus on innovation strategic partnerships and operational excellence have positioned the company for continued growth and scalability across multiple fronts.

This is a milestone as it sets the foundation for continued growth with our approach to operational efficiency and automation, we can continue to scale and grow the business, while maintaining margins and costs. We believe we have achieved economies of scale, where new revenue, we'll have incremental operational costs, but with declining ratios driving us to a healthy net margin business.

Similar to other SaaS businesses.

Technologically we are continuing to hone our AI clinical model, while developing next generation diagnostic technologies. Our focus is to have a suite of diagnostic tools that are available to clinicians for more comprehensive screenings.

And we are now in the process of developing a multi parameter cardiac monitor in preparation of this ultimate goal. We are finalizing biochar pro two our next generation cardiac monitor with an expanded set of capabilities, which we expect to file for FDA by end of Q1 next year.

During the latest quarter, we continued to expand sales of bio Corp. Our next generation cardiac monitoring device strengthening our industry presence and underscoring our dedication to delivering cutting edge health care technology. This includes recent initiatives that continue to build momentum, including the launch of major cardiac monitoring pilot programs with several hospital networks in clinics.

Elevating our path to breakeven. These efforts are anticipated to fuel the rapid adoption of our <unk> pro expanding use across existing and new customer bases.

A long cycle of expansion, we are focused on expanding our strategic partnerships to build complementary distribution channels, where we are in active recently this has culminated in market expansion with contracts in the VA and leading homecare groups. Additionally, we continue to expand our pulmonary and neurology partnerships with leading home based diagnostic companies diversifying our market reach.

In summary, our innovation strategic execution and operational efficiency have position by extra city for sustained growth and profitability in the coming year. Our focus is to expand our commercial team investing profits into commercial expansion to increase market share and drive topline growth, we expect our grocery to improve as we invest profits into commercial expansion.

We remain focused on delivering innovative high quality cardiac care solutions and are confident in our ability to continue driving value for our shareholders, while improving patient outcomes worldwide with that I will turn the call over to our CFO, John <unk> to provide more detailed financial insights.

Thank you well cost, let's review the highlights of our second quarter fiscal 2026.

Our recurring revenues generated as a result of the strong market adoption of our technology as a service subscription model as well as our usage based subscriptions remains robust driven by the popularity of our FDA cleared cardiac monitor devices, especially the nextgen <unk>, which features cellular connectivity.

Atrial fibrillation, a primary contributor to strokes remains a significant focus for our business, while pursuing is already monitored and recorded well over two trillion heartbeats, improving patient outcomes for patients with atrial fibrillation, increasing their chances of earlier medical intervention.

Is not only an improvement in patient outcomes, but also has the potential to deliver significant health care cost savings for both patients and the broader health care system.

The second quarter of fiscal 2006, and at September 32025 revenue increased by 19% compared to the corresponding prior year period to $3 9 million from $3 3 million.

Prior quarter. This growth is reflective of our strategic initiatives and directly impacted our focus on continual clicking a logical advancement. We received further revenue growth in our sales pipeline in coming quarters and are optimistic about delivering both future results, which reflects the fact that our latest flagship device was a bust on cross device.

Speaker #1: Good afternoon and welcome to Biotricity's second quarter, fiscal 2026, financial results and business update conference call. Today's conference is being recorded. As a reminder, this is Biotricity's second quarter, fiscal 2026, ended on September 30, 2025.

Geared towards used in hospitals, and large clinics, where we're continuing to penetrate responsibly.

Technology series accounted for 89% of the call.

Speaker #1: So all figures presented for this period will reflect that end date. Earlier, Biotricity issued its earnings press release for the period, which highlighted financial and operational results.

<unk> total revenue, reflecting strong customer satisfaction and retention on quality support services gross profit for the quarter totaled $3 2 million up 29, 4% from two five months of the prior year period.

Speaker #1: A copy of the press release is available on the Investor Relations section of Biotricity's website, and full financials have been filed with the SEC on Form 10Q and posted on edgar@www.sec.gov.

Our gross profit percentage improved 660 basis points to 81, 9% for this quarter up from 75, 2% in the corresponding prior year quarter.

Speaker #1: Before beginning the company's formal remarks, I'd like to remind listeners today discussions may contain forward-looking statements that reflect management's current views with respect to future events.

This increase is attributable to the expansion of our recording technology through revenue base efficiencies gained through our proprietary AI and improvements on our monitoring on cloud cost structure.

Speaker #1: Any such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. Biotricity does not undertake to update any forward-looking statements except as required.

As part of ourselves initiatives, we continue to search for opportunities to expand our geographic footprint. We serve thousands of cardiologists across hundreds of sensors are in sourcing business model allows us cardiac medical professionals to have direct control over our services enhancing efficiency and enabling broader market penetration.

Speaker #1: At this point, I'm pleased to turn the call over to Biotricity's founder and CEO, Dr. Waqaas Al. Thank you. Please go ahead.

Business development initiatives include expansion into other verticals that are ancillary NASA.

Speaker #2: Hi, everybody. I would like to first thank everybody for joining us today. Fiscal 2026 has been a pivotal year for Biotricity, defined by significant advancements and strategic initiatives that have brought us to the threshold of profitability.

And naturally with our core business.

We continue to investigate those types of opportunities for the future.

Operating expenses for the second quarter were $2 $9 million compared to $2 8 million in the same period last year, which was a five 1% increase our SG&A expenses increased by two 5% a comparative additional spending of over $56000 for this quarter, we added to our R&D expenses increase.

Speaker #2: Our relentless focus on innovation, strategic partnerships, and operational excellence have positioned the company for continued growth and scalability across multiple fronts. This is a milestone as it sets the foundation for continued growth.

Speaker #2: With our approach to operational efficiency and automation, we can continue to scale and grow the business while maintaining margins and costs. We believe we have achieved economies of scale where new revenue will have incremental operational costs, but with declining ratios.

And those by $84000.

As previously discussed we are strategically transformed our sales force to increase efficiency. Our external sales team is focused on longer sales cycles on larger accounts, including independent hospitals and GPO networks.

Speaker #2: Driving us to a healthy net margin business similar to other SaaS-like businesses. Technologically, we are continuing to hone our AI clinical model while developing next-generation diagnostic technologies.

We are contracted number three of the largest GPO networks, which gives us access to sell into more than 90% of hospitals in the U S.

Speaker #2: Our focus is to have a suite of diagnostic tools that are available to clinicians for more comprehensive screenings. To that end, we are now in the process of developing a multi-parameter cardiac monitor.

All of these positive improvements in revenue growth and operating efficiencies through the use of AI and other automation as well as proactive cost management have allowed us to continue to achieve positive free cash flows defined as cash from operations that was available to pay interest and dividends and we have done this for the last five consecutive quarters.

Speaker #2: In preparation for this ultimate goal, we are finalizing BioCore Pro 2, our next-generation cardiac monitor with an expanded set of capabilities, which we expect to file for FDA approval by the end of Q1 next year.

Speaker #2: During the latest quarter, we continued to expand sales of BioCore Pro, our next-generation cardiac monitoring device, strengthening our industry presence and underscoring our dedication to delivering cutting-edge healthcare technology.

<unk> been set on a path to achieve profitability in the next few quarters and five were.

We're pleased that this quarter in the second quarter of fiscal 2026 is the second consecutive quarter of Biocryst in which it was achieved a positive EBITDA. This is an important milestone an indicator of the room mirrors full profitability.

Speaker #2: This includes recent initiatives that continue to build momentum, including the launch of major cardiac monitoring pilot programs with several hospital networks and clinics, accelerating our path to breakeven.

Speaker #2: These efforts are anticipated to fuel the rapid adoption of our BioCore Pro, expanding use across existing and new customer bases. Alongside sales expansion, we have focused on expanding our strategic partnerships to build complementary distribution channels where we are inactive.

The company achieved EBITDA of $373000 this quarter.

Which corresponds to $1 <unk> on a per share basis, a reconciliation of our EBITDA and adjusted EBITDA numbers is available in our 10-Q.

Speaker #2: Recently, this has culminated in market expansion with contracts in the VA and leading home care groups. Additionally, we continue to expand our pulmonary and neurology partnerships with leading home-based diagnostic companies, diversifying our market reach.

We are pleased with the progress made in building our technology, obtaining FDA registration developing effective sales strategies and implementing cost cutting measures. The result has been an improvement in operating results of nearly <unk> $6 million to achieve our second consecutive profitable quarter from operations.

Speaker #2: In summary, our innovations, strategic execution, and operational efficiency have positioned Biotricity for sustained growth and profitability. In the coming year, our focus is to expand our commercial team, investing profits into commercial expansion to increase market share and drive top-line growth.

Which was $274000 for this quarter.

Net loss attributable to common shareholders for the fiscal three month period.

Speaker #2: We expect our growth rate to improve as we invest profits into commercial expansion. We remain focused on delivering innovative, high-quality cardiac care solutions, and are confident in our ability to continue driving value for our shareholders while improving patient outcomes worldwide.

Was $772000 compared to $1 6 million during the corresponding prior year period on a per share basis, we reported a loss per share of $2.09 compared to <unk> 70 <unk>.

Speaker #2: With that, I will turn the call over to our CFO, S. Ayanoglou, to provide more detailed financial.

For the corresponding prior year period.

Looking ahead, we remain committed to advancing our business through commercialization of our bio core bowflex body care products are.

Speaker #3: Thank you, Waqaas. Let's review the highlights of our second quarter, fiscal 2026. Our recurring revenue generated as a result of strong market adoption of our technologies, service subscription model, as well as our usage-based subscriptions, remain robust.

<unk> is truly useful globally and cardiac is the number one climate air condition.

The entire world.

The growing market interest and demand for our suite of products dedicated to climate cardiac disease prevention and management reinforce our confidence in our market position and importantly, our focus on innovation and development continues to yield significant advancements in our remote monitoring solutions for both diagnostic.

Speaker #3: Driven by the popularity of our FDA-cleared cardiac monitor devices, especially the next-gen BioCore Pro, which features cellular connectivity, atrial fibrillation—a primary contributor to strokes—remains a significant focus.

And post diagnostic products, bringing us ever closer again to profitability.

We are excited about the future and confident in our ability to deliver sustained growth and profitability for biocryst.

That concludes our prepared remarks, operator, please open the line for questions.

Thank you.

We will be conducting a question and answer session if you'd like to ask a question. Please press star one on your telephone keypad, a confirmation tone will indicate that your line is in the question queue.

You May press star two to remove yourself from the queue.

For participants using speaker equipment and may be necessary to pick up your handset before pressing the star keys.

One moment, while we poll for questions.

Yeah.

So again, if you'd like to ask a question. Please press star one on your telephone keypad.

Okay, and gentlemen looks like there are no further questions at this time I'd like to turn the conference back.

To management for any closing remarks.

Thank you and thank you all for attending this has been a fantastic quarter for us as we believe it is the moment, we achieved economies of scale.

We're confident that we're on the cusp of profitability, we expect increasing revenues, while maintaining margin. Our focus now is to scale the business investing in the expansion of our commercial team to drive growth and market share if.

If I had to distill our message into key takeaways for the next 12 months they would be as follows one our revenue will continue to increase to our margins will be maintained three we will be profitable anwyl industrial profits into commercial expansion to increase revenue and market share and four we will continue to innovate.

And have a great day.

Thank you and with that everyone that does conclude today's teleconference. We thank you for your participation and you may disconnect. Your lines at this time I don't want to.

Wonderful rest of the theory.

Operator: Today's conference is being recorded. As a reminder, this is Biotricity's second quarter, fiscal 2026, ended on 30 September 2025. All figures presented for this period will reflect that end date. Earlier, Biotricity issued its earnings press release for the period, which highlighted financial and operational results. A copy of the press release is available on the investor relations section of Biotricity's website, and full financials have been filed with the SEC on Form 10Q and posted on edgar@www.sec.gov. Before beginning the company's formal remarks, I'd like to remind listeners today's discussions may contain forward-looking statements that reflect management's current views with respect to future events. Any such statements are subject to risk and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. Biotricity does not undertake to update any forward-looking statements except as required.

Speaker #1: The growing market interest and demand for our suite of products dedicated to chronic cardiac disease prevention and management reinforces our confidence in our market position.

Speaker #1: Importantly, our focus on innovation and development continues to yield significant advancements in our remote monitoring solutions. For both diagnostic and post-diagnostic products, we are bringing ourselves ever closer to profitability.

Speaker #1: We are excited about the future and confident in our ability to deliver sustained growth and profitability for Biotricity. That concludes our prepared remarks. Operator, please open the line for questions.

Speaker #1: questions. Thank you.

Speaker #2: And with that, we will be conducting a question-and-answer session. If you would like to ask a question, please press star one on your telephone keypad.

Operator: At this point, I'm pleased to turn the call over to Biotricity's founder and CEO, Dr. Waqaas Al-Sadiq. Thank you. Please go ahead.

Speaker #2: Confirmation tone will indicate that your line is in the question queue. You may press *2 to remove yourself from the queue. For participants using speaker equipment, it may be necessary to pick up the handset before pressing the star keys.

Waqaas Al-Siddiq: Hi everybody. I would like to first thank everybody for joining us today. Fiscal 2026 has been a pivotal year for Biotricity, defined by significant advancements and strategic initiatives that have brought us to the threshold of profitability. Our relentless focus on innovation, strategic partnerships, and operational excellence has positioned the company for continued growth and scalability across multiple fronts. This is a milestone, as it sets the foundation for continued growth. With our approach to operational efficiency and automation, we can continue to scale and grow the business while maintaining margins and costs. We believe we have achieved economies of scale where new revenue will have incremental operational costs but with declining ratios, driving us to a healthy net margin business, similar to other SaaS-like businesses. Technologically, we are continuing to hone our AI clinical model while developing next-generation diagnostic technologies.

Speaker #2: One moment while we pull for questions. Once again, if you'd like to ask a question, please press star one on your telephone keypad. Okay.

Speaker #2: Gentlemen, it looks like there are no further questions at this time. I'd like to turn the conference back to management for any closing remarks.

Speaker #2: remarks. Thank

Waqaas Al-Siddiq: Our focus is to have a suite of diagnostic tools that are available to clinicians for more comprehensive screenings. To that end, we are now in the process of developing a multi-parameter cardiac monitor. In preparation of this ultimate goal, we are finalizing BioCorp Pro 2, our next-generation cardiac monitor with an expanded set of capabilities, which we expect to file for FDA by end of Q1 2025. During the latest quarter, we continue to expand sales of BioCorp Pro, our next-generation cardiac monitoring device, strengthening our industry presence and underscoring our dedication to delivering cutting-edge healthcare technology. This includes recent initiatives that continue to build momentum, including the launch of major cardiac monitoring pilot programs with several hospital networks and clinics, accelerating our path to breakeven. These efforts are anticipated to fuel the rapid adoption of our BioCorp Pro, expanding use across existing and new customer bases.

Speaker #3: You, and thank you all for attending. This has been a fantastic quarter for us, as we believe it is the moment we achieved economies of scale.

Speaker #3: We are confident that we are on the cusp of profitability and expect increasing revenues while maintaining margins. Our focus now is to scale the business by investing in the expansion of our commercial team to drive growth and market share.

Speaker #3: If I had to distill our message into key takeaways for the next 12 months, they would be as follows. One, our revenue will continue to increase.

Speaker #3: Two, our margins will be maintained. Three, we will be profitable and will invest our profits into commercial expansion to increase revenue and market share.

Speaker #3: And, four, we will continue to innovate. Thank you, and have a great day.

Speaker #3: day. Thank you.

Speaker #2: And with that, teleconference. We thank you for your participation, and you may disconnect your lines at this time. Have a wonderful rest of your day.

Waqaas Al-Siddiq: Alongside sales expansion, we have focused on expanding our strategic partnerships to build complementary distribution channels where we are inactive. Recently, this has culminated in market expansion with contracts in the VA and leading home care groups. Additionally, we continue to expand our pulmonary and neurology partnerships with leading home-based diagnostic companies, diversifying our market reach. In summary, our innovations, strategic execution, and operational efficiency have positioned Biotricity for sustained growth and profitability. In the coming year, our focus is to expand our commercial team, investing profits into commercial expansion to increase market share and drive top-line growth. We expect our growth rate to improve as we invest profits into commercial expansion. We remain focused on delivering innovative, high-quality cardiac care solutions, and are confident in our ability to continue driving value for our shareholders while improving patient outcomes worldwide.

Speaker #2: evening.

Speaker #4: Thanks,

Waqaas Al-Siddiq: With that, I will turn the call over to our CFO, John Ayanoglou, to provide more detailed financial insights.

John Ayanoglou: Thank you, Waqaas. Let's review the highlights of our second quarter, fiscal 2026. Our recurring revenue, generated as a result of strong market adoption of our technology as a service subscription model, as well as our usage-based subscriptions, remains robust, driven by the popularity of our FDA-cleared cardiac monitor devices, especially the next-gen BioCorp Pro, which features cellular conductivity. Atrial fibrillation, a primary contributor to strokes, remains a significant focus for our business. Biotricity has already monitored and recorded well over 2 trillion heartbeats, improving patient outcomes for patients with atrial fibrillation, increasing their chances of earlier medical intervention. This is not only an improvement in patient outcomes, it also has the propensity to deliver significant healthcare cost savings for both patients and the broader healthcare system.

John Ayanoglou: For the second quarter of fiscal 2026 ended 30 September 2025, revenue increased by 19% compared to the corresponding prior year period to $3.9 million from $3.3 million in the prior quarter. This growth is reflective of our strategic initiatives, and directly impacted by our focus on continual technological advancement. We see further revenue growth in our sales pipeline in coming quarters, and are optimistic about delivering those future results, which reflect the fact that our latest flagship device is a best-in-class device geared towards use in hospitals and large clinics, where we continue to penetrate effectively. Technology fees accounted for 89% of the quarter's total revenue, reflecting strong customer satisfaction, retention, and quality support services. Gross profit for the quarter totaled $3.2 million, up 29.4% from $2.5 million of the prior year period.

John Ayanoglou: Our gross profit percentage improved 660 basis points to 81.9% for this quarter, up from 75.3% in the corresponding prior year quarter. This increase is attributable to the expansion of our current technology fee revenue base, efficiencies gained through our proprietary AI, and improvements in our monitoring and cloud cost structure. As part of our sales initiatives, we continue to search for opportunities to expand our geographic footprint. We serve thousands of cardiologists across hundreds of centers. Our insourcing business model allows these cardiac medical professionals to have direct control over our services, enhancing efficiency and enabling broader market penetration. Our business development initiatives include expansion into other verticals that are ancillary, but fit naturally with our core business. We continue to investigate those types of opportunities for the future.

John Ayanoglou: Operating expenses for the second quarter were $2.9 million compared to $2.8 million in the same period last year, which is a 5.1% increase. Our SG&A expenses increased by 2.5%, a comparative additional spending of over $56,000 for this quarter, that we added to our R&D expenses, increasing those by $84,000. As previously discussed, we have strategically transformed our sales force to increase efficiency. Our external sales team is focused on longer sales cycles and larger accounts, including independent hospitals and GPO networks. We are contracted under three of the largest GPO networks, which gives us coveted access to sell into more than 90% of hospitals in the US.

John Ayanoglou: All of these positive improvements in revenue growth and operating efficiencies through the use of AI and other automation, as well as proactive cost management, have allowed us to continue to achieve positive free cash flows, defined as the cash from operations that is available to pay interest and dividends. We've done this for the last five consecutive quarters, and it's been set on a path to achieve profitability in the next few quarters. In fact, we're pleased that this quarter, the second quarter of fiscal 2026, is the second consecutive quarter of Biotricity in which it has achieved a positive EBITDA. This is an important milestone and indicator that we're nearing full profitability. The company achieved EBITDA of $373,000 this quarter, which corresponds to $0.014 on a per-share basis. A reconciliation of our EBITDA and adjusted EBITDA numbers is available in our 10Q.

John Ayanoglou: We are pleased with the progress made in building our technology, obtaining FDA registrations, developing effective sales strategies, and implementing cost-cutting measures. The result has been an improvement in operating results of nearly $0.6 million to achieve our second consecutive profitable quarter from operations, which was $274,000 for this quarter. Net loss attributable to common shareholders for the fiscal three-month period was $772,000 compared to $1.6 million during the corresponding prior year period. On a per-share basis, we reported a loss per share of $0.029 compared to $0.73 for the corresponding prior year period. Looking ahead, we remain committed to advancing our business through commercialization of our BioCorp Pro, BioFlux, and BioCare products. Our tech is truly useful globally, and cardiac is the number one chronic care condition in the entire world.

John Ayanoglou: The growing market interest and demand for our suite of products dedicated to chronic cardiac disease prevention and management reinforce our confidence in our market position. Importantly, our focus on innovation and development continues to yield significant advancements in our remote monitoring solutions for both diagnostic and post-diagnostic products, bringing us ever closer again to profitability. We are excited about the future, and confident in our ability to deliver sustained growth and profitability for Biotricity. That concludes our prepared remarks. Operator, please open the line for questions.

Operator: Thank you. With that, we will be conducting a question-and-answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate that your line is in the question queue. You may press star two to remove yourself from the queue. For participants using speaker equipment, it may be necessary to pick up the handset before pressing the star keys. One moment while we poll for questions. Again, if you'd like to ask a question, please press star one on your telephone keypad. Okay, gentlemen, looks like there are no further questions at this time. I'd like to turn the conference back to management for any closing remarks.

Waqaas Al-Siddiq: Thank you. Thank you all for attending. This has been a fantastic quarter for us, as we believe it is the moment we achieved economies of scale. We are confident that we are on the cusp of profitability and expect increasing revenues while maintaining margin. Our focus now is to scale the business, investing in the expansion of our commercial team to drive growth and market share. If I had to distill our message into key takeaways for the next 12 months, they would be as follows: One, our revenue will continue to increase. Two, our margins will be maintained. Three, we will be profitable and will invest our profits into commercial expansion to increase revenue and market share. Four, we will continue to innovate. Thank you and have a great day.

Operator: Thank you. With that, everyone, this does conclude today's teleconference. We thank you for your participation, and you may disconnect your lines at this time. Have a wonderful rest of your evening.